معرفی
Habibe YILMAZ is an Assistant Professor at Trakya University Faculty of Pharmacy, Department of Pharmaceutical Biotechnology. She currently serves as Deputy Director of the Foreign Relations Application and Research Center (2024-2027) and has held various administrative positions including Department Head of Pharmacy Technology (2023-2023) and Department Head of Pharmaceutical Biotechnology (2020-2024). She is actively involved in multiple university committees including the University-Industry Cooperation Commission, Course and Exam Program Preparation Committee, Education and Training Commission, and Internal Control Monitoring and Guidance Commission. She is also conducting postdoctoral research at the University of Nottingham Academic Unit of Mental Health and Clinical Neurosciences (2024-2025) focusing on P-gp Targeted Nanoconjugate evaluation in Blood-Brain-Barrier models.
- Bachelor's Degree (2010): Ege University, Faculty of Science, Department of Biochemistry
- Master's Degree (2012): Ege University, Institute of Science, Department of Biochemistry
- PhD (2017): Ege University, Institute of Science, Department of Biochemistry
Dr. YILMAZ's research focuses on nanomedicine and targeted drug delivery systems, particularly magnetic nanoparticles for cancer therapy and other medical applications. Her work spans pharmaceutical biotechnology, nanobiotechnology, and the development of novel drug delivery systems including pH-sensitive nano-antibiotics, ultrasound-triggered nanobubbles, and folate receptor targeted delivery systems. She has made significant contributions to the understanding of nanoparticle-based therapies for various conditions including cancer, osteomyelitis, and cerebral small vessel disease. Her research integrates biochemistry, pharmaceutical sciences, and nanotechnology to create innovative therapeutic approaches.
Analysis of her recent publications reveals a strong focus on nanomedicine applications, with particular emphasis on targeted drug delivery systems for cancer therapy. Her work demonstrates expertise in developing various nanoformulations including magnetic nanoparticles, pH-sensitive carriers, and dual-drug delivery systems. Recent research has expanded into neurological applications, particularly cerebral small vessel disease, while maintaining strong contributions to cancer nanomedicine and vaccine development as evidenced by her work on COVID-19 DNA vaccines.
- Best poster award at International Sustainability in Life Congress for 'Dual-Drug Loaded Liposomal Nanoantibiotic System' (2024)
- Best oral presentation at 8th BBBB International Conference on Pharmaceutical Sciences (2019)
- Second place award at Life Sciences and Health Project Competition (2015)
- Multiple best poster awards at European Pharma Congress (2015)
- Third place poster award at Drug Chemistry Congress (2014)
- First place in 'The Best Hypothesis' competition at Cancer Nanomedicine Symposium (2013)
Dr. YILMAZ has served as a mentor and advisor for numerous research projects, particularly those focused on nanomedicine applications. She has been involved in significant research grants including TÜBİTAK 1007 project 'Monoclonal Antibody Active Ingredient Biobetter Drug Development and Production for Cancer and Osteoporosis Treatment' (2017-2018) and TÜBİTAK 1003 project on magnetic and ultrasound targeted drug carrier systems for lung cancer treatment. Her editorial work includes serving as Editor for 'Recent Progress in Pharmaceutical Nanobiotechnology: A Medical Perspective' published by Bentham Science Publishers.
She leads research in the development of P-gp targeted nanocarriers and has established patent-protected technologies including 'Ultrasound Susceptible Magnetic Directed Nano Drug Carrier System' (EPO PATENT, 2025) and 'Targeted Drug Delivery System To Be Used in Treating Osteomyelitis' (WIPO PCT PATENT, 2020).
